Indian biosimilars market may reach $40 bn by 2030 – Feedback

Biosimilars presents a $240 billion global opportunity for Indian pharmaceuticals industry, while the domestic market is expected to reach $40 billion by 2030, according to ‘Assocham-Sathguru’ report released today.

The report was released by Prof D Swaminadhan, President and Director General, Jawaharlal Nehru Institute of Advanced Studies (JNIAS) at Assocham-Department of Pharmaceuticals Conference on BioPharma here. “Indian biosimilars industry was close to $300 million in 2015. Domestic sales are close to $250 million growing at CAGR of 14 per cent, while exports contributed close to $51 million.” “However, with the introduction of a new regulatory policy in India and increased affordability that biosimilars offer, the domestic market is expected to grow at an accelerated pace and reach the target of $40 billion by 2030 and will command 20 per cent share in global market,” the report said. The biosimilars opportunity is nascent today and the 2016 estimated market size was only $2.2 billion. However, the recent USFDA approvals and market penetration stories emerging from Europe herald in the next phase of growth in this industry.

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *